Dr. Buse's clinical and research interests are in the prevention and treatment of diabetes and its complications. He has clinical practices at the UNC Highgate Specialty Center in Durham, NC and the Salem Center in Winston-Salem, NC. He is the principal investigator for a number of trials conducted by the research team at Highgate and an investigator in other trials on UNC campus and in the TraCS Institute. He enjoys lecturing about diabetes.
Industry Expertise (3)
Areas of Expertise (8)
Best Doctors in America (professional)
Elected by peers via Best Doctors, Inc.
Top Doctors – Endocrinology (professional)
Awarded by Business North Carolina.
Robert J Glaser Clinical Star (professional)
Awarded by Washington University.
American College of Endocrinology.
Duke University: Ph.D., Medicine 1986
Duke University: M.D., Medicine 1986
Dartmouth College: A.B., Biochemistry 1979
- American Association of Clinical Endocrinologists
- American Diabetes Association
- Endocrine Society
- Society of General Internal Medicine
Media Appearances (3)
John Buse to chair federal diabetes education program
National Institutes of Health News & Events online
John Buse, M.D., Ph.D., of the University of North Carolina at Chapel Hill School of Medicine, has been named the new chair of the National Diabetes Education Program (NDEP) ...
John B. Buse, MD, PhD of Chapel Hill, NC, Elected American Diabetes Association President, Medicine & Science
PR Newswire online
As President, Medicine & Science, Dr. Buse is one of the principal officers of the ADA and will serve as the principal spokesperson and advocate of the Association on scientific and medical matters ...
UNC’S John B. Buse on Developments in Diabetes
Science Watch online
In the last decade, Buse has published 20 papers with more than 100 citations each. During that time, he has also co-authored two articles each cited more than 1,000 citations times ...
ABSTRACT: In the ACCORD trial, intensive treatment of patients with type 2 diabetes and high cardiovascular (CV) risk was associated with higher all-cause and CV mortality. Post hoc analyses have failed to implicate rapid reduction of glucose, hypoglycemia, or specific drugs as the causes of this finding. We hypothesized that exposure to injected insulin was quantitatively associated with increased CV mortality.
ABSTRACT: IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
ABSTRACT: Pharmacoepidemiologic studies are often expected to be sufficiently powered to study rare outcomes, but there is sequential loss of power with implementation of study design options minimizing bias. We illustrate this using a study comparing pancreatic cancer incidence after initiating dipeptidyl-peptidase-4 inhibitors (DPP-4i) versus thiazolidinediones or sulfonylureas.
ABSTRACT: IDegLira is a novel combination of a basal insulin (insulin degludec [IDeg]) and a glucagon-like peptide-1 receptor agonist (liraglutide) available as a once-daily injection for patients with type 2 diabetes (T2D). The present post hoc analyses evaluated whether IDegLira was consistently effective regardless of the stage of T2D progression.
ABSTRACT: Delayed-release metformin (Met DR) is formulated to deliver drug to the lower bowel to leverage the gut-based mechanisms of metformin action with lower plasma exposure. Met DR was assessed in two studies. Study 1 compared the bioavailability of single daily doses of Met DR to currently available immediate-release metformin (Met IR) and extended-release metformin (Met XR) in otherwise healthy volunteers. Study 2 assessed glycemic control in subjects with type 2 diabetes (T2DM) over 12 weeks.